Literature DB >> 8682615

Occurrence of the antibody against human papillomavirus type 16 virion protein L2 in patients with cervical cancer and dysplasia.

T Kanda1, H Teshima, K Katase, S Umezawa, H Watabe, H Takahashi, T Onda, K Yoshiike.   

Abstract

Infection with HPV 16 is believed to be a major risk factor for cervical cancer. To correlate HPV 16 infection and carcinogenesis in the cervix, we examined by ELISA 326 sera from healthy females and patients with cervical cancer, cervical intraepithelial neoplasia, or dysplasia, for the presence of IgG antibodies against HPV 16 virion protein L2 expressed in Escherichia coli. Whereas 2 of 208 were positive in the healthy females, 4 of 23 and 6 of 90 were positive in the patients with cervical cancer and dysplasia, respectively. The findings indicate that infection with HPV 16 is related to cancer and dysplasia of the cervix. The anti-L2 antibody did not occur coincidentally with the antibodies against the HPV 16 early proteins E4 and E7, which are specifically but independently associated with patients with cervical cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8682615     DOI: 10.1159/000150431

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  2 in total

1.  Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.

Authors:  Joshua W Wang; Subhashini Jagu; Wai-Hong Wu; Raphael P Viscidi; Anne Macgregor-Das; Jessica M Fogel; Kihyuck Kwak; Sai Daayana; Henry Kitchener; Peter L Stern; Patti E Gravitt; Cornelia L Trimble; Richard B S Roden
Journal:  Clin Vaccine Immunol       Date:  2015-05-13

2.  Anti-L1 antibody-bound HPV16 pseudovirus is degraded intracellularly via TRIM21/proteasomal pathway.

Authors:  Meiying Li; Jianmei Huang; Guonan Zhang; Jianming Huang; Yi Zhu; Ziyi Huang
Journal:  Virol J       Date:  2022-05-26       Impact factor: 5.913

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.